An antibody that coats a cell can lead to its removal in three different ways: immune cells that kill it, cells that swallow it, or blood proteins that damage its membrane. Seeing the coat does not show which of these happened.
Opsonisation means coating a target with molecules that help immune clearance. The antibody's Fc region can then connect that coat to effector cells or to complement, and three mechanisms name different downstream jobs. In antibody-dependent cellular cytotoxicity (ADCC) an effector cell, with the natural killer cell as the familiar example, triggers damage or death in a coated target, typically through an Fc gamma receptor such as CD16 engaging target-bound IgG. In antibody-dependent cellular phagocytosis (ADCP) a phagocyte such as a macrophage engulfs the coated target. In complement-dependent cytotoxicity (CDC) the complement protein C1q recognises a suitable arrangement of Fc regions and the cascade can end in membrane attack complexes. ADCC is not an exclusive cell-identity label: other immune populations can contribute antibody-dependent cytotoxicity.
The three routes can overlap and no universal ranking exists. Isotype and Fc design, target density, inhibitory signals and the availability of effectors or complement shape the result. Evidence differs in kind. Clynes et al. (2000) used mouse tumour models, including xenografts treated with the humanised antibodies trastuzumab and rituximab, and found that engagement of Fc gamma receptors on effector cells was a dominant component of in vivo antibody activity, with the inhibitory receptor FcgammaRIIB regulating it. Gül et al. (2014) imaged mice directly: liver macrophages (Kupffer cells) sampled circulating tumour cells without eliminating them, whereas antitumour antibody treatment produced rapid phagocytosis that depended on the Fc receptors FcgammaRI and FcgammaRIV. Diebolder et al. (2014) showed in cell and biochemical systems that ordered IgG hexamers assembled on the target surface recruit and activate C1, and that this could be manipulated to block or enhance complement killing across all four human IgG subclasses. None of these is a human treatment-benefit result.
What each step shows is separate. Fc-receptor binding is not completed ADCC or ADCP. A phagocyte touching a target, or sampling a fragment, is not internalisation of a whole viable cell. Complement deposition (coating) is an earlier step than a membrane pore, and a pore is a different observation from measured lysis. Assays therefore name their output: target death for ADCC, the fraction of phagocytes with verified internalised targets for ADCP, membrane damage with active complement for CDC (heat-inactivated or depleted complement tests complement dependence). They use viable targets, defined antibody concentrations, no-antibody and target-negative controls, and report exposure time and effector-to-target ratio. Binding or reporter activation alone is an earlier readout, and stronger activity in a dish does not establish clinical benefit or healthy-tissue safety.
In plain words · FCGR3A encodes CD16A, an IgG Fc receptor involved in NK-cell responses to antibody-coated targets. Binding alone does not establish completed killing.
Showing the target this term concerns: FCGR3A.
Shares Antibody and the tag education-immunology-2026-11.
Shares NK cell and the tag education-immunology-2026-11.
Shares Antibody isotypes and Fc silencing, Fc engineering / effector function, Antibody.
Shares FCGR3A, Fc engineering / effector function, NK cell, ADCC (antibody-dependent cellular cytotoxicity).
Shares Fc engineering / effector function, ADCC (antibody-dependent cellular cytotoxicity).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/